| Date | Time | Source | |
| 02/28/2013 | 2:02AM | RNSNON | Immupharma PLC ImmuPharma Commences Trading on Stuttgart Exchange
TIDMIMM RNS Number : 8448Y Immupharma PLC 28 February 2013 FOR IMMEDIATE RELEASE 28 FEBRUARY 2013 RNS REACH ImmuPharma PLC Commences Trading on the Stuttgart Stock Exchange ImmuPharma PLC (LSE: IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, is pleased to announces that it... More...>> |
| 01/28/2013 | 4:33AM | RNSNON | Immupharma PLC CNRS Confirms Lupuzor's (TM) Effectiveness
TIDMIMM RNS Number : 4761W Immupharma PLC 28 January 2013 FOR IMMEDIATE RELEASE 28 JANUARY 2013 RNS REACH CNRS Confirms Lupuzor's (TM) Effectiveness ImmuPharma PLC (LSE: IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, is pleased to announce that its key scientific collaboration... More...>> |
| 11/05/2012 | 2:00AM | RNSNON | Immupharma PLC Lupuzor Presentation
TIDMIMM RNS Number : 2719Q Immupharma PLC 05 November 2012 FOR IMMEDIATE RELEASE 5 NOVEMER 2012 RNS REACH ImmuPharma to Present Lupuzor(TM) Phase IIb Abstract / Clinical Paper at 2012 Annual ACR Meeting, Washington, D.C. Presentation Date: 14 November 2012 ImmuPharma PLC (LSE: IMM), ("ImmuPharma" or the "Company"), the... More...>> |
| 09/07/2012 | 6:12AM | RNSNON | Immupharma PLC Rodman and Renshaw Conference
TIDMIMM RNS Number : 7713L Immupharma PLC 07 September 2012 FOR IMMEDIATE RELEASE 7 SEPTEMBER 2012 RNS REACH ImmuPharma to Present at Rodman and Renshaw Annual Global Investment Conference, New York Tuesday 11 September 2012 ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development... More...>> |
| 07/11/2012 | 2:00AM | RNSNON | Immupharma PLC Voted Best Medical Research & Development Company
TIDMIMM RNS Number : 3670H Immupharma PLC 11 July 2012 FOR IMMEDIATE RELEASE 11 July 2012 RNS REACH ImmuPharma PLC Voted Best Medical Research and Development Company, Europe 2012 ImmuPharma PLC (LSE: IMM) ("ImmuPharma" or the "Company"), the specialist discovery and development pharmaceutical company, has been voted "Best... More...>> |
| 07/09/2012 | 2:00AM | RNSNON | Immupharma PLC New Corporate Website
TIDMIMM RNS Number : 1708H Immupharma PLC 09 July 2012 FOR IMMEDIATE RELEASE 9 July 2012 RNS REACH IMMUPHARMA LAUNCHES NEW CORPORATE WEBSITE PROVDING GREATER CLARITY ON LUPUZOR, CANCER AND ITS DEVELOPMENT PIPELINE ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug development company has today... More...>> |
| 02/29/2012 | 2:02AM | RNSNON | Appoints Head of Investor Relations
TIDMIMM RNS Number : 3054Y Immupharma PLC 29 February 2012 FOR IMMEDIATE RELEASE 29 FEBRUARY 2012 ImmuPharma plc Appoints Head of Investor Relations ImmuPharma plc (AIM: IMM), the specialist drug development company, is pleased to announce that it has appointed Lisa Baderoon as Head of Investor Relations. Lisa Baderoon... More...>> |
| 11/03/2011 | 4:20AM | DJN | ImmuPharma In Lupuzor Licensing Talks As FDA Says Trials Can Begin
U.K. drug discovery company ImmuPharma PLC (IMM.LN) Thursday said U.S. regulators have given it the green light to begin a Phase III trial for its flagship drug Lupuzor, and said it is in talks with pharmaceutical companies regarding a potential licensing deal for the Lupus treatment. ImmuPharma said the U.S. Food and... More...>> |
| 03/23/2011 | 1:26PM | DJN | UPDATE: UK Government Budget Gives Boost To Big Pharma, Biotechs
The U.K. life sciences sector got a boost Wednesday when the British government backed a number of industry demands designed to stimulate drug research. U.K. Chancellor of the Exchequer George Osborne told lawmakers the government will boost tax relief for research and development carried out by small and medium-sized... More...>> |
| 03/23/2011 | 1:06PM | DJN | UK Government Budget Gives Boost To Big Pharma, Biotechs
The U.K. life sciences sector got a boost Wednesday when the British government backed a number of industry demands designed to stimulate drug research. U.K. Chancellor of the Exchequer George Osborne told lawmakers the government will boost tax relief for research and development carried out by small and medium-sized... More...>> |
| 11/11/2010 | 4:36PM | DJN | Human Genome, Glaxo To Face FDA Panel For Lupus Drug
Human Genome Sciences Inc. (HGSI) and GlaxoSmithKline Plc (GSK, GSK.LN) are seeking to take a significant step next week in getting regulatory approval for the first new treatment to fight the autoimmune disease lupus in more than 50 years. A U.S. Food and Drug Administration panel will decide Tuesday whether the companies... More...>> |
| 06/28/2010 | 2:00AM | RNSNON | Presentation at the International Congress
TIDMIMM RNS Number : 2912O Immupharma PLC 28 June 2010 ? +------------------------------+------------------------------+ | For Immediate Release | 28 June 2010 | +------------------------------+------------------------------+ ImmuPharma PLC LUPUS 2010 CONGRESS Announces presentation of the LupuzorTM phase IIb trial at... More...>> |
| 06/28/2010 | 2:00AM | RNSNON | Presentation at the International -2-
world economic downturn threatens the creativity and risk taking so necessary for further discovery and the financing of the research, medical education, and the delivery of both established and newly discovered therapies that are essential for improving the lives of persons with lupus. So LUPUS 2010 occurs at a time of... More...>> |
